329 related articles for article (PubMed ID: 23324593)
41. Calcium signaling in Parkinson's disease.
Calì T; Ottolini D; Brini M
Cell Tissue Res; 2014 Aug; 357(2):439-54. PubMed ID: 24781149
[TBL] [Abstract][Full Text] [Related]
42. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
[TBL] [Abstract][Full Text] [Related]
43. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
[TBL] [Abstract][Full Text] [Related]
44. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.
Devi L; Raghavendran V; Prabhu BM; Avadhani NG; Anandatheerthavarada HK
J Biol Chem; 2008 Apr; 283(14):9089-100. PubMed ID: 18245082
[TBL] [Abstract][Full Text] [Related]
45. Relationship between mitochondria and α-synuclein: a study of single substantia nigra neurons.
Reeve AK; Park TK; Jaros E; Campbell GR; Lax NZ; Hepplewhite PD; Krishnan KJ; Elson JL; Morris CM; McKeith IG; Turnbull DM
Arch Neurol; 2012 Mar; 69(3):385-93. PubMed ID: 22410447
[TBL] [Abstract][Full Text] [Related]
46. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
[TBL] [Abstract][Full Text] [Related]
47. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.
Lee HJ; Baek SM; Ho DH; Suk JE; Cho ED; Lee SJ
Exp Mol Med; 2011 Apr; 43(4):216-22. PubMed ID: 21415592
[TBL] [Abstract][Full Text] [Related]
48. Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease.
Büttner S; Habernig L; Broeskamp F; Ruli D; Vögtle FN; Vlachos M; Macchi F; Küttner V; Carmona-Gutierrez D; Eisenberg T; Ring J; Markaki M; Taskin AA; Benke S; Ruckenstuhl C; Braun R; Van den Haute C; Bammens T; van der Perren A; Fröhlich KU; Winderickx J; Kroemer G; Baekelandt V; Tavernarakis N; Kovacs GG; Dengjel J; Meisinger C; Sigrist SJ; Madeo F
EMBO J; 2013 Nov; 32(23):3041-54. PubMed ID: 24129513
[TBL] [Abstract][Full Text] [Related]
49. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
Pal GD; Ouyang B; Serrano G; Shill HA; Goetz C; Stebbins G; Metman LV; Driver-Dunckley E; Mehta SH; Caviness JN; Sabbagh MN; Adler CH; Beach TG;
Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
[TBL] [Abstract][Full Text] [Related]
50. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management.
Phillipson OT
Ageing Res Rev; 2017 Nov; 40():149-167. PubMed ID: 28986235
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
52. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
[TBL] [Abstract][Full Text] [Related]
53. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
54. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
Gründemann J; Schlaudraff F; Haeckel O; Liss B
Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
[TBL] [Abstract][Full Text] [Related]
55. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
56. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
57. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
58. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
59. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
60. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
